Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|November 11, 2022

New LUGPA president discusses this year's meeting and 2023 goals

Author(s)Urology Times staff

"We have more younger members here at the annual meeting than we've ever had before. We want to make that a priority," says Evan R. Goldfischer, MD, MBA, FACS.

Evan R. Goldfischer, MD, MBA, FACS, who officially began his term as LUGPA president, discusses highlights from the 2022 Annual LUGPA Meeting and the group's goals for the upcoming year. Dr. Goldfischer is a urologist at Premier Medical Group in Poughkeepsie, New York.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Matthew Truesdale, MD, on IsoPSA performance with and without mpMRI

ByMatthew Truesdale, MD, FACS

July 4th 2026

Gopa Iyer, MD, highlights data on anti-Nectin-4 ADC for metastatic urothelial carcinoma

ByGopa Iyer, MD

July 1st 2026

Fred Saad, MD, highlights PSA end points from the phase 3 PSMAddition trial

ByFred Saad, MD, CQ, FRCS, FCAHS

June 24th 2026

Enzalutamide plus talazoparib demonstrates clinical activity in mHSPC

ByHannah Clarke

June 23rd 2026

Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD

ByAmy M. Pearlman, MD,Larry Lipshultz, MD,Rachel Rubin, MD

June 23rd 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Matthew Truesdale, MD, on IsoPSA performance with and without mpMRI

Published VAPOR 2 data evaluate water vapor ablation for localized prostate cancer

Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

The UroOnc Minute: Making Appointments More Effective, With David Canes, MD

From OR to office: How Break Wave changes urology practice workflow